CO2023015036A2 - Composición inmunogénica contra la influenza - Google Patents
Composición inmunogénica contra la influenzaInfo
- Publication number
- CO2023015036A2 CO2023015036A2 CONC2023/0015036A CO2023015036A CO2023015036A2 CO 2023015036 A2 CO2023015036 A2 CO 2023015036A2 CO 2023015036 A CO2023015036 A CO 2023015036A CO 2023015036 A2 CO2023015036 A2 CO 2023015036A2
- Authority
- CO
- Colombia
- Prior art keywords
- immunogenic composition
- against influenza
- composition against
- antigens
- influenza
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
- 101710176177 Protein A56 Proteins 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a composiciones y métodos para la preparación, fabricación y uso terapéutico de vacunas de ácido ribonucleico que comprenden moléculas polinucleotídicas que codifican uno o más antígenos de la influenza, como los antígenos de hemaglutinina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183624P | 2021-05-03 | 2021-05-03 | |
| US202163184201P | 2021-05-04 | 2021-05-04 | |
| US202163197325P | 2021-06-04 | 2021-06-04 | |
| US202163261784P | 2021-09-28 | 2021-09-28 | |
| PCT/IB2022/053995 WO2022234417A1 (en) | 2021-05-03 | 2022-04-29 | Immunogenic composition against influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023015036A2 true CO2023015036A2 (es) | 2023-11-20 |
Family
ID=81603777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0015036A CO2023015036A2 (es) | 2021-05-03 | 2023-11-03 | Composición inmunogénica contra la influenza |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362372A1 (es) |
| EP (1) | EP4333880A1 (es) |
| JP (1) | JP2024517229A (es) |
| KR (1) | KR20240004862A (es) |
| AU (1) | AU2022268706A1 (es) |
| BR (1) | BR112023022928A2 (es) |
| CA (1) | CA3218913A1 (es) |
| CO (1) | CO2023015036A2 (es) |
| IL (1) | IL308194A (es) |
| MX (1) | MX2023013004A (es) |
| WO (1) | WO2022234417A1 (es) |
| ZA (1) | ZA202310755B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11898186B1 (en) | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| WO2024126809A1 (en) * | 2022-12-15 | 2024-06-20 | Sanofi | Mrna encoding influenza virus-like particle |
| CN118267376A (zh) * | 2022-12-29 | 2024-07-02 | 康希诺(上海)生物研发有限公司 | 一种核酸递送载体及其制备方法和用途 |
| WO2024171017A1 (en) * | 2023-02-13 | 2024-08-22 | Pfizer Inc. | Immunogenic composition against influenza |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| CA3170743A1 (en) * | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
-
2022
- 2022-04-29 JP JP2023567246A patent/JP2024517229A/ja active Pending
- 2022-04-29 KR KR1020237041563A patent/KR20240004862A/ko active Search and Examination
- 2022-04-29 BR BR112023022928A patent/BR112023022928A2/pt unknown
- 2022-04-29 AU AU2022268706A patent/AU2022268706A1/en active Pending
- 2022-04-29 EP EP22722898.8A patent/EP4333880A1/en active Pending
- 2022-04-29 MX MX2023013004A patent/MX2023013004A/es unknown
- 2022-04-29 CA CA3218913A patent/CA3218913A1/en active Pending
- 2022-04-29 US US17/733,566 patent/US20220362372A1/en active Pending
- 2022-04-29 IL IL308194A patent/IL308194A/en unknown
- 2022-04-29 WO PCT/IB2022/053995 patent/WO2022234417A1/en active Application Filing
-
2023
- 2023-11-03 CO CONC2023/0015036A patent/CO2023015036A2/es unknown
- 2023-11-21 ZA ZA2023/10755A patent/ZA202310755B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022234417A1 (en) | 2022-11-10 |
| CA3218913A1 (en) | 2022-11-10 |
| EP4333880A1 (en) | 2024-03-13 |
| BR112023022928A2 (pt) | 2024-01-23 |
| US20220362372A1 (en) | 2022-11-17 |
| KR20240004862A (ko) | 2024-01-11 |
| MX2023013004A (es) | 2023-11-15 |
| IL308194A (en) | 2024-01-01 |
| AU2022268706A1 (en) | 2023-11-30 |
| AU2022268706A9 (en) | 2023-12-07 |
| JP2024517229A (ja) | 2024-04-19 |
| ZA202310755B (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015036A2 (es) | Composición inmunogénica contra la influenza | |
| BR112016024644A2 (pt) | vacinas de ácido nucleico | |
| WO2018089851A3 (en) | Influenza vaccine | |
| BR112018008078A2 (pt) | vacina de vírus influenza de amplo espectro | |
| BR112018008102A2 (pt) | vacina de vírus sincicial respiratório | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| EP3916091A3 (en) | Dry powder composition comprising long-chain rna | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| CO6331297A2 (es) | Composiciones adyuvantes novedosas | |
| BR112017000313A2 (pt) | sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| ECSP18034035A (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico | |
| BR112017005821A2 (pt) | formulação aquosa, método para a preparação de uma formulação aquosa, conjunto, método para a preparação de uma composição farmacêutica, composição farmacêutica e método para quimicamente estabilizar uma formulação aquosa | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| BR112012022939A2 (pt) | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| HN2012000217A (es) | Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos. | |
| CL2020001901A1 (es) | Vacunas contra virus de la gripe y usos de las mismas. | |
| BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
| MX2024004177A (es) | Composiciones inmunogenicas de lnp y metodos de los mismos. | |
| BR112018069079A2 (pt) | construtos de alfavírus vivos atenuados e métodos e usos dos mesmos |